ArticleInfection and drug resistance2023
Molecular and Clinical Characteristics of Carbapenem-Resistant
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Genomic Epidemiology of NDM-1 Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Application value of Xpert Carba-R combined with LAMP in the diagnosis and prognosis of carbapenem-resistant Gram-negative bacilli pneumonia.Microbiology spectrum · 2026Article
- Genomic characterisation and antimicrobial resistance ofFrontiers in cellular and infection microbiology · 2026Article
- A One Health Perspective on the Plasmid Backbone Preference and Evolutionary Adaptation ofInfection and drug resistance · 2026Article
- Genome-Wide DNA Methylation and RNA Analysis Reveal Epigenetic and Transcriptomic Changes in Carbapenem-Resistant Klebsiella pneumoniae Strains.Current microbiology · 2025Article
- Article
- Prevalence and molecular characterisation of multi-drug resistant ST11 hypervirulent Klebsiella pneumoniae in a teaching hospital.BMC microbiology · 2025Article
- Genomic Characterization of Carbapenemase-ProducingMicroorganisms · 2025Article
- Genome Sequencing and Comparative Genomic Analysis of Multidrug-ResistantInfection and drug resistance · 2025Article
- Genomic characterization of ST11-KL25 hypervirulent KPC-2-producing multidrug-resistantiScience · 2024Article
- In Vitro Synergistic Effect of Colistin with Fosfomycin Against Carbapenem-Resistant Klebsiella pneumoniae.Cureus · 2024Article
- Prevalence of ST1049-KL5 carbapenem-resistant Klebsiella pneumoniae with a blaCommunications biology · 2024Article
- Genomic insights and antimicrobial resistance profiles of CRKP and non-CRKP isolates in a Beijing geriatric medical center: emphasizing theFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem resistant Klebsiella pneumoniae (CRKP) is an independent risk factor for nosocomial infection which poses a serious threat to human health. How to prevent and suppress CRKP infection and explore its drug resistance mechanisms have become a huge challenge and possesses immediate significance. Methods: A total of 45 CRKP strains isolated from hospitalized patients in Zhongnan Hospital of Wuhan University were collected from August 2018-December 2020. The strain's identification and antimicrobial susceptibility tests were performed using the VITEK 2 automated identification instrument. Single molecule DNA sequencing of 45 CRKP isolates was performed by the third generation high-throughput sequencing technology. Results: The results were analyzed by multi locus sequence typing (MLST) and phylogenetic analysis. Antimicrobial susceptibility showed that 45 CRKP isolates were multi-drug resistant strains, and the resistance rates to common antibiotics were as high as 68%. Whole genome sequencing results showed that the CRKP strains carried multiple drug resistance genes and virulence factors. MLST analysis found two different sequence types (ST), of which 44 were ST11 and 1 was ST1049. Conclusion: Through whole genome sequencing (WGS), we found multiple drug-resistant genes and virulence factors, and there was obvious dominant microbiota. The source was mainly related to nosocomial infection. The ST11-KPC Klebsiella pneumoniae was the main type, which was consistent with the most common type in China. We identified several dominant microbiotas which may serve as a target in the clinical prevention and treatment of severe bacterial infections. Our finding may have a role for guiding clinical antibiotic choosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.